$2.55T
Total marketcap
$183.1B
Total volume
BTC 50.05%     ETH 15.87%
Dominance

Mirati Therapeutics MRTX Stock

58.7 USD {{ price }} 0.000000% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
4.12B USD
LOW - HIGH [24H]
0.0000 - 0.0000 USD
VOLUME [24H]
0 USD
{{ volume }}
P/E Ratio
0
Earnings per share
0 USD

Mirati Therapeutics Price Chart

Mirati Therapeutics MRTX Financial and Trading Overview

Mirati Therapeutics stock price 58.7 USD
Previous Close 36.83 USD
Open 36.66 USD
Bid 0 USD x 900
Ask 0 USD x 800
Day's Range 36.03 - 39.17 USD
52 Week Range 35.7 - 101.3 USD
Volume 1.56M USD
Avg. Volume 1M USD
Market Cap 2.27B USD
Beta (5Y Monthly) 1.019366
PE Ratio (TTM) N/A
EPS (TTM) 0 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 66.29 USD

MRTX Valuation Measures

Enterprise Value 1.29B USD
Trailing P/E N/A
Forward P/E -3.7982457
PEG Ratio (5 yr expected) 0.04
Price/Sales (ttm) 120.01395
Price/Book (mrq) 2.626896
Enterprise Value/Revenue 68.09
Enterprise Value/EBITDA -1.68

Trading Information

Mirati Therapeutics Stock Price History

Beta (5Y Monthly) 1.019366
52-Week Change -29.14%
S&P500 52-Week Change 20.43%
52 Week High 101.3 USD
52 Week Low 35.7 USD
50-Day Moving Average 42.15 USD
200-Day Moving Average 54.08 USD

MRTX Share Statistics

Avg. Volume (3 month) 1M USD
Avg. Daily Volume (10-Days) 1.05M USD
Shares Outstanding 58.19M
Float 36.53M
Short Ratio 6.72
% Held by Insiders 6.76%
% Held by Institutions 115.17%
Shares Short 7.11M
Short % of Float 13.52%
Short % of Shares Outstanding 12.21%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) -4071.10%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -39.16%
Return on Equity (ttm) -69.80%

Income Statement

Revenue (ttm) 18.89M USD
Revenue Per Share (ttm) 0.33 USD
Quarterly Revenue Growth (yoy) 910.89%
Gross Profit (ttm) -519791000 USD
EBITDA -765819008 USD
Net Income Avi to Common (ttm) -737067008 USD
Diluted EPS (ttm) -12.96
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 907.67M USD
Total Cash Per Share (mrq) 15.6 USD
Total Debt (mrq) 51.13M USD
Total Debt/Equity (mrq) 5.93 USD
Current Ratio (mrq) 7.539
Book Value Per Share (mrq) 14.835

Cash Flow Statement

Operating Cash Flow (ttm) -600283008 USD
Levered Free Cash Flow (ttm) -316056256 USD

Profile of Mirati Therapeutics

Country United States
State CA
City San Diego
Address 3545 Cray Court
ZIP 92121
Phone 858 332 3410
Website https://www.mirati.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 587

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Q&A For Mirati Therapeutics Stock

What is a current MRTX stock price?

Mirati Therapeutics MRTX stock price today per share is 58.7 USD.

How to purchase Mirati Therapeutics stock?

You can buy MRTX shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Mirati Therapeutics?

The stock symbol or ticker of Mirati Therapeutics is MRTX.

Which industry does the Mirati Therapeutics company belong to?

The Mirati Therapeutics industry is Biotechnology.

How many shares does Mirati Therapeutics have in circulation?

The max supply of Mirati Therapeutics shares is 70.15M.

What is Mirati Therapeutics Price to Earnings Ratio (PE Ratio)?

Mirati Therapeutics PE Ratio is 0.00000000 now.

What was Mirati Therapeutics earnings per share over the trailing 12 months (TTM)?

Mirati Therapeutics EPS is 0 USD over the trailing 12 months.

Which sector does the Mirati Therapeutics company belong to?

The Mirati Therapeutics sector is Healthcare.

Mirati Therapeutics MRTX included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
NASDAQ Composite Total Return I XCMP 19565.06 USD
+0.82
19553.78 USD 19740.18 USD
NASDAQ Global Select Market Com NQGS 7837.41 USD
+0.85
7832.7 USD 7908.95 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD
Nasdaq US 700 Small Cap Index NQUS700SC 2078.81 USD
-0.4
2075.76 USD 2093.28 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2568.29 USD
+0.16
2566.7 USD 2581.47 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD